MaxCyte, Inc. MXCT
Regular-session close
After hours · Nov 13, 4:00 PM ET
- YTD
- -23.23%
- 1 year
- -21.19%
- Market cap
- 122.87M
- Revenue (ttm)
- 45.60M
- Profit margin
- -78.37%
- EPS (ttm)
- -0.26
- Shares out
- 105.48M
- Forward P/E
- -10.41
- YTD return
- -23.23%
- 1-year return
- -21.19%
- Volume
- 1.25M
- Avg volume
- 980.66K
- Open
- 1.16
- Previous close
- 1.19
- Day's range
- 1.12 – 1.20
- 52-week range
- 0.643 – 1.81
- Beta
- 1.16
- Analysts
- Strong Buy
- Price target
- 8.67 (+628.3%)
5D -0.12 (-9.09%)
Key statistics
- Enterprise value
- 311.73M
- PEG ratio
- 0.00
- Price / sales
- 9.39
- Price / book
- 2.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.00%
- Free cash flow
- -7.75M
- Total cash
- 153.83M
- Total debt
- 18.32M
- Return on equity
- -16.00%
- Short % of float
- 2.93%
- 50-day average
- 3.75
- 200-day average
- 4.11
Fundamental scorecard
7 of 25 checks passed on MXCT’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.13 | -0.11 | +0.02 | +15.38% |
| Aug 6, 2024 | Jun 1, 2024 | -0.14 | -0.09 | +0.05 | +35.71% |
| Aug 6, 2024 | Jun 1, 2024 | -0.14 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.14 | -0.09 | +0.05 | +35.71% |
| May 7, 2024 | Mar 1, 2024 | -0.14 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | -0.10 | -0.05 | +0.05 | +50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 23, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Mar 13, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Mar 13, 2024 | BTIG | main | Buy | Buy |
| Nov 29, 2023 | Craig-Hallum | init | — | Buy |
| Oct 5, 2023 | Stephens & Co. | reit | Overweight | Overweight |
| Mar 28, 2023 | Stephens & Co. | reit | — | Overweight |
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- maxcyte.com
News
MaxCyte, Inc. (MXCT) Q3 2026 Earnings Call Transcript
MaxCyte Q3 2026 Earnings Call Transcript
12 Health Care Stocks Moving In Tuesday's After-Market Session
MaxCyte Q3 Earnings Call Highlights MaxCyte To Acquire Akron BioProducts From Arcline Investment Management For Total Consideration Of $151.8M, Comprising $105M In Cash And 20.6M MXCT Shares Worth ~$26.8M
MaxCyte Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $10.152M Beat $7.481M Estimate
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on MXCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AL-WAKEEL YASIR B | Director | Stock Award(Grant) | Jun 10, 2024 | 21,367 |
| BALTHROP PATRICK J SR | Director | Stock Award(Grant) | Jun 10, 2024 | 21,367 |
| COLLINS CYNTHIA | Director | Stock Award(Grant) | Oct 13, 2024 | 51,679 |
| DOUGLAS RICHARD H | Director | Stock Award(Grant) | Jun 10, 2024 | 121,367 |
| ERCK STANLEY C | Director | Sale | Oct 31, 2024 | 269,118 |
| HEMRAJANI REKHA | Director | Stock Award(Grant) | Jun 10, 2024 | 21,367 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.03% | 8,488,107 | 34.46M | Sep 29, 2024 |
| Cadian Capital Management, LP | 7.75% | 8,188,948 | 33.25M | Sep 29, 2024 |
| Vanguard Group Inc | 5.46% | 5,775,268 | 23.45M | Sep 29, 2024 |
| Vitruvian Partners, LLP | 4.77% | 5,043,356 | 20.48M | Sep 29, 2024 |
| Morgan Stanley | 4.56% | 4,817,132 | 19.56M | Sep 29, 2024 |
| Millennium Management Llc | 3.97% | 4,192,865 | 17.02M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.79% | 2,952,768 | 11.99M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.56% | 2,710,468 | 11.00M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.57% | 1,658,764 | 6.73M | Sep 29, 2024 |
| Morgan Stanley Inst Fund Inc-Inception Port | 1.10% | 1,160,845 | 4.71M | Sep 29, 2024 |
| Fidelity Advisor Equity Growth Fund | 1.07% | 1,126,821 | 4.57M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 1.01% | 1,069,199 | 4.34M | Aug 30, 2024 |
